H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Vanda today and set a price target of $20.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ram Selvaraju has given his Buy rating due to a combination of factors including the potential approval of Vanda’s drug, tradipitant, for motion sickness. The FDA is currently reviewing the New Drug Application for tradipitant, and the process is progressing as planned with a target action date set for late December 2025. This drug could become the first new treatment for motion sickness in over forty years, which presents a significant market opportunity.
Additionally, the potential market for tradipitant in motion sickness is substantial, with estimates suggesting it could reach over $700 million globally. Moreover, Vanda’s other pipeline products, such as HETLIOZ for jet lag disorder and Bysanti for bipolar I disorder and schizophrenia, are also under regulatory review, offering further upside potential. These factors collectively contribute to the optimistic outlook and the Buy rating for Vanda’s stock.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 19.7% and a 53.92% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Microbot Medical, and Genmab.